Pilot Study Of Wellstar's Thermal Imaging Device Completed By Duke University Medical Center

Main Category: Medical Devices / Diagnostics
Also Included In: Dermatology;  Clinical Trials / Drug Trials
Article Date: 24 Sep 2008 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Wellstar International, Inc. (OTCBB: WLSI), a developer of thermal imaging, diagnostic software and equipment, announced today that an important, pilot evaluation of the Company's TMI infrared thermal imaging device has been completed by Duke University Medical Center. The device was utilized by physicians in the Wound Management Institute at Duke as a surveillance and assessment tool for the prevention of pressure ulcers and deep tissue injury. More information on the results of this study will be made available as soon as Wellstar receives the complete report.

About Duke University Medical Center

Duke University Medical Center, the hub of the Duke University Health System, is consistently ranked among the top ten health care organizations, and among the top five academic health centers, in the United States. The youngest of the nation's leading medical centers, Duke has earned an international reputation for innovation and excellence. Duke operates one of the country's largest clinical and biomedical research enterprises, and quickly translates advances in technology and medical knowledge into improved patient care. From new cardiac surgery techniques to stem cell transplants to wound care management, Duke scientists and physicians have pioneered many diagnostic and therapeutic "firsts," many of which are now standard medical practice around the nation.

About Wellstar International, Inc

Wellstar International, Inc., through its wholly owned operating subsidiary Trillenium Medical Imaging, Inc. (TMI), is poised to become a leading diagnostic company in the health care industry. TMI has developed and is marketing fully calibrated and functional, thermal imaging systems that utilize state-of-the-art infrared technologies and proprietary software to accurately and cost-effectively measure physiological changes in the human body. More information on the Company and its unique diagnostic software and product line is available on Wellstar's corporate Website, by visiting: http://www.wellstar.us.

Forward-Looking Statements

This press release contains statements, which may constitute 'forward-looking statements' within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Wellstar International, Inc.